# BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)

> **NCT02398929** · PHASE4 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 100 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Bisoprolol 2.5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02398929
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2021-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398929, "BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02398929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*